QuantSignals › Forecasts › MOH
KATY's daily model path, its record on MOH, and the options read. Prices as of the Nov 10, 2026 close · page updated Nov 10, 2026.
Last close
$206.35
Nov 10, 2026 · +1.48% on the day
KATY call
SELL
run Nov 6, 2026
Path end (20 sessions)
$202.89
−2.92% from $208.99
Path range
−3.1% to +0.4%
lowest and highest point of the path
Replay record on MOH
3/3 hits
100% · 0 misses
KATY's latest public daily path for Molina Healthcare, from its run on Nov 6, 2026, points down, which KATY labels SELL. Starting from the $208.99 close, the path ends 20 sessions later near $202.89 (−2.92%), around Dec 4, and ranges between −3.08% and +0.38% along the way. That is a model path, not a price target.
Since that run, MOH has closed at $206.35 on Nov 10, 2026, −1.26% from the start, 2 of 20 sessions in. So far the move agrees with the path. The call is scored after session 20.
On MOH, KATY's replay record is 3 hits and 0 misses in 3 tested calls (100%), above its 50.1% rate across all tickers. Its most recent completed replay call expected +0.72% and MOH moved +6.12%: a miss on direction.
Daily closes, with KATY's Nov 6, 2026 path drawn from its start close to its end point; the shaded wedge spans the path's lowest and highest points.
The KATY apps and extension show the newest MOH path as soon as it runs, with the full step-by-step line on the chart. They are free to install; live forecasts need KATY Premium or an FST membership.
Every public MOH path this page has captured, scored on the close 20 sessions after its start: a BUY is a hit if that close is higher, a SELL if it is lower.
| Run | Call | Start close | Path end | Outcome at 20 sessions |
|---|---|---|---|---|
| Nov 6, 2026 | SELL | $208.99 | $202.89 (−2.92%) | Open, 2/20 sessions · −1.26% so far |
3 hits, 0 misses and 1 neutral in 3 replayed MOH calls (100% on direction; 100% finished inside the 1.5% band; average path error 6.08%). Across all tickers KATY's replay hit rate is 50.1% over 1,023 calls (BUY > +1.5%, SELL < -1.5% on the 20-step path). Replays re-run the model on past data it did not see; they are not live trades.
KATY re-forecast the 20 sessions that just finished without seeing them. It expected +0.72%; the actual move was +6.12% (direction miss, average path error 5.58%).
| Step | Session | Model path | Actual close | Path vs actual |
|---|---|---|---|---|
| 1 | Oct 12, 2026 | $198.30 | $204.36 | −2.97% |
| 5 | Oct 16, 2026 | $199.03 | $207.36 | −4.02% |
| 10 | Oct 23, 2026 | $197.91 | $209.15 | −5.37% |
| 15 | Oct 30, 2026 | $196.39 | $204.78 | −4.10% |
| 20 | Nov 6, 2026 | $198.34 | $208.99 | −5.10% |
KATY's latest public daily path for MOH (run Nov 6, 2026) is SELL: from $208.99 it ends near $202.89 (−2.92%) after 20 sessions. It is a model path, not a price target. The newest path is in the KATY apps (free to install; live forecasts need KATY Premium or an FST membership).
In replay, KATY called the direction of MOH right 3 times and wrong 0 times out of 3 tested calls (100%). Public calls on this page are scored after 20 sessions and listed above, misses included.
KATY is a time-series foundation model that reads the recent daily bars of MOH and draws the most likely path for the next 20 sessions. A path that ends more than 1.5% up is a BUY, more than 1.5% down a SELL, and anything in between is NEUTRAL. It is not investment advice.
KATY draws this forecast on your own charts: in TradingView with the Chrome extension, or on your phone. The extension and apps are free to install; live forecasts need KATY Premium or an FST membership.
Healthcare & biotech
Most viewed
Not investment advice. KATY's output is a model path, not a price target and not a recommendation to buy or sell. Model forecasts are often wrong; the hit and miss counts on this page are shown so you can judge that yourself. Trading involves risk of loss. Data from QS Research; prices are daily closes and may lag.